Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

While the Windows maker did not attribute the activity to a specific threat actor, the use of VS Code tasks and Vercel ...

Threat actors are abusing Pastebin comments to distribute a new ClickFix-style attack that tricks cryptocurrency users into executing malicious JavaScript in their browser, allowing attackers to ...

The Microsoft Defender team has discovered a coordinated campaign targeting software developers through malicious repositories posing as legitimate Next.js projects and technical assessment materials, ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

Windows 11 feeling bloated? Sophia Script lets you reshape the OS from the inside out. Here's how it works.

Market researchers expect strong growth in AI infrastructure in 2026, while rising storage prices will dampen demand for end devices. Faster, bigger, smarter — the efforts of manufacturers and ...